CDKN1A and non-small cell lung carcinoma: Several studies have found that, lincRNA-p21 has significantly reduced in multiple cancers such as gastric cancer [12], chronic lymphocytic leukemia [13], hepatocellular carcinoma [6], non-small cell lung cancer [14], colorectal cancer [15], diffuse large B cell lymphoma [16], and prostate cancer [7].